Therapeutic options for hydrating airway mucus in cystic fibrosis

Pharmacology

Volumn 95, Issue 3-4, 2015, Pages 117-132

  Tildy, Bernadett E ^a   Rogers, Duncan F ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Bronchitol; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator gene; Hypertonic saline; Ivacaftor; Lung; Mannitol; Moli1901; Mucus; Mucus hydration

Indexed keywords

4 PHENYLBUTYRIC ACID; AMILORIDE DERIVATIVE; AMINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ATALUREN; BORTEZOMIB; CAPSAICIN; CHAPERONE; CURCUMIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; GENISTEIN; IVACAFTOR; LANCOVUTIDE; LUMACAFTOR; MANNITOL; MIGLUSTAT; OSMOTIC AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RESPIRATORY TRACT AGENT; SILDENAFIL; SODIUM CHLORIDE; THAPSIGARGIN;

APICAL MEMBRANE; CHANNEL GATING; EPITHELIAL LINING FLUID; GENE MUTATION; HUMAN; HYDRATION; ION CONDUCTANCE; LUNG ALVEOLUS EPITHELIUM CELL; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; META ANALYSIS (TOPIC); MOLECULAR GENETICS; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; RESPIRATORY TRACT MUCOSA; REVIEW; ANIMAL; CYSTIC FIBROSIS; GENETICS; METABOLISM; MUCUS; RESPIRATORY SYSTEM;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MANNITOL; MUCUS; RESPIRATORY SYSTEM; SALINE SOLUTION, HYPERTONIC;

EID: 84926137770     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000377638     Document Type: Review

References (160)

1. Rogers DF, Barnes PJ: Treatment of airway mucus hypersecretion. Ann Med 2006; 38: 116-125.
2. Derichs N, Jin BJ, Song Y, et al: Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching. FASEB J 2011; 25: 2325-2332.
3. Kerem B, Rommens JM, Buchanan JA, et al: Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080.
4. Rowntree RK, Harris A: The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003; 67: 471-485.
5. Rogan MP, Stoltz DA, Hornick DB: Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011; 139: 1480-1490.
6. Osborne L, Santis G, Schwarz M, et al: Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene. Hum Genet 1992; 89: 653-658.
7. Rich DP, Anderson MP, Gregory RJ, et al: Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990; 347: 358-363.
8. Hwang TC, Sheppard DN: Gating of the CFTR Cl-channel by ATP-driven nucleotidebinding domain dimerization. J Physiol 2009; 587: 2151-2161.
9. Boucher RC: Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007; 13: 231-240.
10. Boucher RC: Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007; 58: 157-170.
11. Boucher RC: New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23: 146-158.
12. Robinson M, Hemming AL, Regnis JA, et al: Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900-903.
13. Boucher RC: Human airway ion transport. Part two. Am J Respir Crit Care Med 1994; 150: 581-593.
14. Robinson M, Regnis JA, Bailey DL, et al: Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 1503-1509.
15. Regnis JA, Robinson M, Bailey DL, et al: Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994; 150: 66-71.
16. Button B, Boucher RC; University of North Carolina Virtual Lung Group: Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol 2008; 163: 189-201.
17. Rasgado-Flores H, Krishna Mandava V, Siman H, et al: Effect of apical hyperosmotic sodium challenge and amiloride on sodium transport in human bronchial epithelial cells from cystic fibrosis donors. Am J Physiol Cell Physiol 2013; 305:C1114-C1122.
18. King M, Dasgupta B, Tomkiewicz RP, et al: Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156: 173-177.
19. Assouline G, Leibson V, Danon A: Stimulation of prostaglandin output from rat stomach by hypertonic solutions. Eur J Pharmacol 1977; 44: 271-273.
20. Haxel BR, Schafer D, Klimek L, et al: Prostaglandin E2 activates the ciliary beat frequency of cultured human nasal mucosa via the second messenger cyclic adenosine monophosphate. Eur Arch Otorhinolaryngol 2001; 258: 230-235.
21. Donaldson SH, Bennett WD, Zeman KL, et al: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-250.
22. Elkins MR, Robinson M, Rose BR, et al: A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240.
23. Rosenfeld M, Davis S, Brumback L, et al: Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol 2011; 46: 666-671.
24. Rosenfeld M, Ratjen F, Brumback L, et al: Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012; 307: 2269-2277.
25. Subbarao P, Stanojevic S, Brown M, et al: Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013; 188: 456-460.
26. Beydon N, Robinson PD: Early intervention for newborns screened for cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 409-410.
27. Robinson M, Daviskas E, Eberl S, et al: The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678-685.
28. Daviskas E, Rubin BK: Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med 2013; 7: 65-75.
29. Tiddens HA, Donaldson SH, Rosenfeld M, et al: Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively Pediatr Pulmonol 2010; 45: 107-117.
30. Boucher RC: Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007; 261: 5-16.
31. Daviskas E, Anderson SD, Eberl S, et al: Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999; 159: 1843-1848.
32. Bilton D, Robinson P, Cooper P, et al: Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-1080.
33. Aitken ML, Bellon G, De Boeck K, et al: Longterm inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185: 645-652.
34. Teper A, Jaques A, Charlton B: Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cyst Fibros 2011; 10: 1-8.
35. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT01883531.
36. Shoshani T, Augarten A, Gazit E, et al: Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992; 50: 222-228.
37. Dalemans W, Barbry P, Champigny G, et al: Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991; 354: 526-528.
38. Lewis HA, Buchanan SG, Burley SK, et al: Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 2004; 23: 282-293.
39. Haardt M, Benharouga M, Lechardeur D, et al: C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 1999; 274: 21873-21877.
40. Kerem E: Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Pediatr Pulmonol 2005; 40: 183-196.
41. Derichs N: Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013; 22: 58-65.
42. Howard M, Frizzell RA, Bedwell DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-469.
43. Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/-mouse carrying a human CFTR-G542X transgene. J Mol Med 2002; 80: 595-604.
44. Smyth A, Lewis S, Bertenshaw C, et al: Casecontrol study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63: 532-535.
45. Welch EM, Barton ER, Zhuo J, et al: PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
46. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al: Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182: 1262-1272.
47. Kerem E, Hirawat S, Armoni S, et al: Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727.
48. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT01140451.
49. Clunes MT, Boucher RC: Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008; 8: 292-299.
50. Rowe SM, Verkman AS: Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013, DOI: 10.1101/cshperspect.a009761.
51. Chanoux RA, Rubenstein RC: Molecular chaperones as targets to circumvent the CFTR defect in cystic fibrosis. Front Pharmacol 2012; 3: 137.
52. Kopito RR: Biosynthesis and degradation of CFTR. Physiol Rev 1999; 79:S167-S173.
53. Denning GM, Anderson MP, Amara JF, et al: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-764.
54. Sato S, Ward CL, Krouse ME, et al: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996; 271: 635-638.
55. Fischer H, Fukuda N, Barbry P, et al: Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 2001; 281:L52-L57.
56. Zhang XM, Wang XT, Yue H, et al: Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. J Biol Chem 2003; 278: 51232-51242.
57. Hutt D, Balch WE: Cell biology. The proteome in balance. Science 2010; 329: 766-767.
58. Nieddu E, Pollarolo B, Merello L, et al: F508del-CFTR rescue: a matter of cell stress response. Curr Pharm Des 2013; 19: 3476-3496.
59. Alberti S, Bohse K, Arndt V, et al: The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 2004; 15: 4003-4010.
60. Choo-Kang LR, Zeitlin PL: Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 2001; 281:L58-L68.
61. Imai J, Maruya M, Yashiroda H, et al: The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome. EMBO J 2003; 22: 3557-3567.
62. Welch WJ, Brown CR: Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1996; 1: 109-115.
63. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT00016744.
64. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT00590538.
65. Rubenstein RC, Zeitlin PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-490.
66. Rubenstein RC, Egan ME, Zeitlin PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100: 2457-2465.
67. Rubenstein RC, Zeitlin PL: Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 2000; 278:C259-C267.
68. Egan ME, Glockner-Pagel J, Ambrose C, et al: Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8: 485-492.
69. Egan ME, Pearson M, Weiner SA, et al: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304: 600-602.
70. Grubb BR, Gabriel SE, Mengos A, et al: SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol 2006; 34: 355-363.
71. Song Y, Sonawane ND, Salinas D, et al: Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 2004; 279: 40629-40633.
72. Dragomir A, Bjorstad J, Hjelte L, et al: Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2004; 322: 447-451.
73. Mall M, Kunzelmann K: Correction of the CF defect by curcumin: hypes and disappointments. BioEssays 2005; 27: 9-13.
74. Harada K, Okiyoneda T, Hashimoto Y, et al: Curcumin enhances cystic fibrosis transmembrane regulator expression by downregulating calreticulin. Biochem Biophys Res Commun 2007; 353: 351-356.
75. Gelman JS, Sironi J, Berezniuk I, et al: Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One 2013; 8:e53263.
76. Trzcinska-Daneluti AM, Ly D, Huynh L, et al: High-content functional screen to identify proteins that correct F508del-CFTR function. Mol Cell Proteomics 2009; 8: 780-790.
77. Vij N, Fang S, Zeitlin PL: Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006; 281: 17369-17378.
78. Norez C, Noel S, Wilke M, et al: Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006; 580: 2081-2086.
79. Lubamba B, Lebacq J, Lebecque P, et al: Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179: 1022-1028.
80. Farinha CM, Amaral MD: Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 2005; 25: 5242-5252.
81. Okiyoneda T, Niibori A, Harada K, et al: Role of calnexin in the ER quality control and productive folding of CFTR; differential effect of calnexin knockout on wild-type and DeltaF508 CFTR. Biochim Biophys Acta 2008; 1783: 1585-1594.
82. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT00742092.
83. Leonard A, Lebecque P, Dingemanse J, et al: A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cystic Fibrosis 2012; 11: 231-236.
84. Jenkins BA, Glenn LL: Miglustat effects on the basal nasal potential differences in cystic fibrosis. J Cyst Fibros 2013; 12: 88.
85. Leonard A, Lebecque P, Dingemanse J, et al: Miglustat effects on the basal nasal potential differences in cystic fibrosis. J Cyst Fibros 2013; 12: 89.
86. Hutt DM, Herman D, Rodrigues AP, et al: Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010; 6: 25-33.
87. Wang X, Venable J, LaPointe P, et al: Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127: 803-815.
88. Basile A, Pascale M, Franceschelli S, et al: Matrine modulates HSC70 levels and rescues DeltaF508-CFTR. J Cell Physiol 2012; 227: 3317-3323.
89. Van Goor F, Straley KS, Cao D, et al: Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290:L1117-L1130.
90. Kim Chiaw P, Wellhauser L, Huan LJ, et al: A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010; 78: 411-418.
91. Okiyoneda T, Veit G, Dekkers JF, et al: Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 2013; 9: 444-454.
92. Loo TW, Bartlett MC, Clarke DM: Bithiazole correctors rescue CFTR mutants by two different mechanisms. Biochemistry 2013; 52: 5161-5163.
93. Pedemonte N, Lukacs GL, Du K, et al: Smallmolecule correctors of defective DeltaF508-CFTR cellular processing identified by highthroughput screening. J Clin Invest 2005; 115: 2564-2571.
94. Ren HY, Grove DE, De La Rosa O, et al: VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 2013; 24: 3016-3024.
95. Clancy JP, Rowe SM, Accurso FJ, et al: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67: 12-18.
96. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT01768663.
97. Pyle LC, Ehrhardt A, Mitchell LH, et al: Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am J Physiol Lung Cell Mol Physiol 2011; 301:L587-L597.
98. Pasyk S, Li C, Ramjeesingh M, Bear CE: Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosiscausing mutation associated with severe disease. Biochem J 2009; 418: 185-190.
99. Yu H, Burton B, Huang CJ, et al: Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11: 237-245.
100. Jih KY, Hwang TC: VX-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA 2013; 110: 4404-4409.
101. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT01784419.
102. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT01060566.
103. Boyle MP, Bell SC, Konstan MW, et al: A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe-508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2: 527-538.
104. Hwang TC, Wang F, Yang IC, et al: Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997; 273:C988-C998.
105. Yu YC, Miki H, Nakamura Y, et al: Curcumin and genistein additively potentiate G551DCFTR. J Cyst Fibros 2011; 10: 243-252.
106. Ai T, Bompadre SG, Wang X, et al: Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol 2004; 65: 1415-1426.
107. Sohma Y, Yu YC, Hwang TC: Curcumin and genistein: the combined effects on diseaseassociated CFTR mutants and their clinical implications. Curr Pharm Des 2013; 19: 3521-3528.
108. Conger BT, Zhang S, Skinner D, et al: Comparison of cystic fibrosis transmembrane conductance regulator (CFTR) and ciliary beat frequency activation by the CFTR modulators Genistein, VRT-532, and UCCF-152 in primary sinonasal epithelial cultures. JAMA Otolaryngol Head Neck Surg 2013; 139: 822-827.
109. Drumm ML, Wilkinson DJ, Smit LS, et al: Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991; 254: 1797-1799.
110. Cheng SH, Gregory RJ, Marshall J, et al: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-834
111. Grubb B, Lazarowski E, Knowles M, et al: Isobutylmethylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia. Am J Respir Cell Mol Biol 1993; 8: 454-460.
112. Lubamba B, Lebacq J, Reychler G, et al: Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 2011; 37: 72-78.
113. Dhooghe B, Noel S, Bouzin C, et al: Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice. PLoS One 2013; 8:e77314.
114. Robert R, Carlile GW, Pavel C, et al: Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008; 73: 478-489.
115. Lubamba B, Lecourt H, Lebacq J, et al: Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 506-515.
116. Leier G, Bangel-Ruland N, Sobczak K, et al: Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem 2012; 29: 775-790.
117. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT01132482.
118. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials. gov/ct2/show/NCT00659529.
119. Chen JH, Stoltz DA, Karp PH, et al: Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010; 143: 911-923.
120. Itani OA, Chen JH, Karp PH, et al: Human cystic fibrosis airway epithelia have reduced Cl-conductance but not increased Na + conductance. Proc Natl Acad Sci USA 2011; 108: 10260-10265.
121. Kirk KL: Being positive: revisiting the elevated sodium permeability hypothesis in cystic fibrosis. J Physiol 2013; 591: 3675-3676.
122. Hollenhorst MI, Richter K, Fronius M: Ion transport by pulmonary epithelia. J Biomed Biotechnol 2011; 2011: 174306.
123. Althaus M: ENaC inhibitors and airway rehydration in cystic fibrosis: state of the art. Curr Mol Pharmacol 2013; 6: 3-12.
124. Hirsh AJ, Sabater JR, Zamurs A, et al: Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004; 311: 929-938.
125. Hirsh AJ, Zhang J, Zamurs A, et al: Pharmacological properties of N-(3, 5-diamino-6-chloropyrazine-2-carbonyl)-N-4-[4-(2, 3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008; 325: 77-88.
126. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/study/NCT00274313.
127. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00852839.
128. Hirsh AJ, St George J, Thelin W, et al: RGS-9411: a potential aerosol pharmacotherapy for CF. Am J Respir Crit Care Med 2009; 179:A1195.
129. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00800579.
130. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00999531.
131. O'Riordan TG, Donn KH, Hodsman P, et al: Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv 2014; 27: 200-208.
132. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT01025713.
133. Hunt T, Atherton-Watson HC, Axford J, et al: Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines. Bioorg Med Chem Lett 2012; 22: 929-932.
134. Hunt T, Atherton-Watson HC, Collingwood SP, et al: Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: alphabranched quaternary amines. Bioorg Med Chem Lett 2012; 22: 2877-2879.
135. Maekawa A, Kakizoe Y, Miyoshi T, et al: Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens 2009; 27: 181-189.
136. Coote K, Atherton-Watson HC, Sugar R, et al: Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 2009; 329: 764-774.
137. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00506792.
138. Rowe SM, Reeves G, Hathorne H, et al: Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. Chest 2013; 144: 200-207.
139. Passero CJ, Carattino MD, Kashlan OB, et al: Defining an inhibitory domain in the gamma subunit of the epithelial sodium channel. Am J Physiol Renal Physiol 2010; 299:F854-F861.
140. Vallon V, Rieg T: Regulation of renal NaCl and water transport by the ATP/UTP/P2Y2 receptor system. Am J Physiol Renal Physiol 2011; 301:F463-F475.
141. Namkung W, Yao Z, Finkbeiner WE, et al: Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J 2011; 25: 4048-4062.
142. Lazarowski ER, Boucher RC: Purinergic receptors in airway epithelia. Curr Opin Pharmacol 2009; 9: 262-267.
143. Olivier KN, Bennett WD, Hohneker KW, et al: Acute safety and effects on mucociliary clearance of aerosolized uridine 5-triphosphate +/-amiloride in normal human adults. Am J Respir Crit Care Med 1996; 154: 217-223.
144. Yerxa BR, Sabater JR, Davis CW, et al: Pharmacology of INS37217 [P(1)-(uridine 5 )-P(4)-(2-deoxycytidine 5 )tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 2002; 302: 871-880.
145. Monroe JS, Tomas N, Seiko FO, et al: Denufosol stimulates chloride transport, inhibits sodium absorption and restores airway surface liquid layer in primary airway epithelial cells from CF patients. Am J Respir Crit Care Med 2011; 183:A6123.
146. ClinicalTrials.gov. A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/study/NCT00625612.
147. ClinicalTrials.gov. A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/study/NCT00357279.
148. Accurso FJ, Moss RB, Wilmott RW, et al: Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011; 183: 627-634.
149. Ratjen F, Durham T, Navratil T, et al: Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012; 11: 539-549.
150. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT01181622.
151. Stick SM, Sly PD: Exciting new clinical trials in cystic fibrosis: infants need not apply. Am J Respir Crit Care Med 2011; 183: 1577-1578.
152. Melvin JE, Yule D, Shuttleworth T, et al: Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol 2005; 67: 445-469.
153. Moody M, Pennington C, Schultz C, et al: Inositol polyphosphate derivative inhibits Na + transport and improves fluid dynamics in cystic fibrosis airway epithelia. Am J Physiol Cell Physiol 2005; 289:C512-C520.
154. Traynor-Kaplan AE, Moody M, Nur M, et al: INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia. Am J Respir Cell Mol Biol 2010; 42: 105-112.
155. Tian Y, Schreiber R, Wanitchakool P, et al: Control of TMEM16A by INO-4995 and other inositolphosphates. Br J Pharmacol 2013; 168: 253-265.
156. Cloutier MM, Guernsey L, Sha'afi RI: Duramycin increases intracellular calcium in airway epithelium. Membr Biochem 1993; 10: 107-118.
157. Sheth TR, Henderson RM, Hladky SB, et al: Ion channel formation by duramycin. Biochim Biophys Acta 1992; 1107: 179-185.
158. Grasemann H, Stehling F, Brunar H, et al: Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007; 131: 1461-1466.
159. ClinicalTrials.gov: A service of the US National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00671736.
160. Lee TW, Southern KW: Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst Rev 2013; 09:CD005599.